Humanigen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 22 2020 - 4:30PM
Business Wire
Management presentation Wednesday, September 23
at 10:50 a.m. EDT
Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), announced
today that management will present a company overview and business
update at the Oppenheimer Fall Healthcare Life Sciences &
MedTech Summit at 10:50 a.m. EDT, Wednesday, September 23,
2020.
The conference is being held in a virtual format. A live webcast
of the presentation may be accessed at
https://wsw.com/webcast/oppenheimer5/hgen/2688354. Archived replay
will be available on the Company website for 30 days following the
event.
About Humanigen, Inc.
Humanigen, Inc. is developing its portfolio of clinical and
pre-clinical therapies for the treatment of cancers and infectious
diseases via its novel, cutting-edge GM-CSF neutralization and
gene-knockout platforms. We believe that our GM-CSF neutralization
and gene-editing platform technologies have the potential to reduce
the inflammatory cascade associated with coronavirus infection. The
company’s immediate focus is to prevent or minimize the cytokine
release syndrome that precedes severe lung dysfunction and ARDS in
serious cases of SARS-CoV-2 infection. The company is also
exploring the effectiveness of its GM-CSF neutralization
technologies (either through the use of lenzilumab as a
neutralizing antibody or through GM-CSF gene knockout) in
combination with other CAR-T, bispecific or natural killer (NK) T
cell engaging immunotherapy treatments to break the
efficacy/toxicity linkage, including to prevent and/or treat
graft-versus-host disease (GvHD) in patients undergoing allogeneic
hematopoietic stem cell transplantation (HSCT). Additionally,
Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in
combination with Yescarta® (axicabtagene ciloleucel) in patients
with relapsed or refractory large B-cell lymphoma in a clinical
collaboration. For more information, visit www.humanigen.com.
Forward-Looking Statements
This release contains forward-looking statements.
Forward-looking statements reflect management's current knowledge,
assumptions, judgment and expectations regarding future performance
or events. Although management believes that the expectations
reflected in such statements are reasonable, they give no assurance
that such expectations will prove to be correct and you should be
aware that actual events or results may differ materially from
those contained in the forward-looking statements. Words such as
"will," "expect," "intend," "plan," "potential," "possible,"
"goals," "accelerate," "continue," and similar expressions identify
forward-looking statements. Forward-looking statements are subject
to a number of risks and uncertainties including, but not limited
to, the various risks and uncertainties described in the "Risk
Factors" sections and elsewhere in the Company's periodic and other
filings with the Securities and Exchange Commission.
All forward-looking statements are expressly qualified in their
entirety by this cautionary notice. You should not place undue
reliance on any forward-looking statements, which speak only as of
the date of this release. We undertake no obligation to revise or
update any forward-looking statements made in this press release to
reflect events or circumstances after the date hereof or to reflect
new information or the occurrence of unanticipated events, except
as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200922006017/en/
Media Sean Leous Westwicke, an ICR company
sean.leous@westwicke.com 646-866-4012
Investors Victoria Meissner, MD Westwicke, an ICR company
victoria.meissner@westwicke.com 646-677-1837
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024